论文部分内容阅读
Introduction Anthracycline-containing regimens (CHOP and CHOP-like regimens) are still the cornerstone of elderly patients with diffuse large B-cell lymphoma (DLBCL),although the therapeutic response is acceptable,high incidence of co-morbidities and treatment-related adverse effects including cardiac and hematologic toxicities are major obstacle in clinical practice,and management of elderly DLBCL patients remains a great challenge.